Table 2 Subject characteristics by chemotherapy categories (ITT population)
Fosaprepitant regimen | Control regimen | |||||||
|---|---|---|---|---|---|---|---|---|
n (%) | GI or colorectal cancers (n = 135) | Lung cancer (n = 129) | Breast cancer (n = 110) | Gynecologic cancer (n = 81) | GI or colorectal cancers (n = 132) | Lung cancer (n = 125) | Breast cancer (n = 121) | Gynecologic cancer (n = 71) |
Single-day regimens | ||||||||
Single MEC | 4 (3.0) | 12 (9.3) | 10 (9.1) | 9 (11.1) | 4 (3.0) | 21 (16.8) | 3 (2.5) | 7 (9.9) |
MEC + ≥1 LEC | 24 (17.8) | 96 (74.4) | 90 (81.8) | 72 (89) | 16 (12.1) | 88 (70.4) | 106 (87.6) | 61 (85.9) |
MEC + MEC | 0 | 0 | 0 | 0 | 1 (0.8) | 0 | 1 (0.8) | 1 (1.4) |
Multiple-day regimens | ||||||||
MEC (day 1) + ≥1 LEC beyond day 1 | 100 (74.1) | 18 (14.0) | 0 | 0 | 94 (71.2) | 14 (11.2) | 0 | 2 (2.8) |
MEC (day 1) + ≥1 MEC + ≥1 LEC | 5 (3.7) | 0 | 0 | 0 | 15 (11.4) | 0 | 0 | 0 |
Non-MEC regimens or no MEC on day 1 | ||||||||
LEC only | 2 (1.5) | 0 | 8 (7.3) | 0 | 2 (1.5) | 1 (0.8) | 8 (6.6) | 0 |
Chemotherapy on day 2 onlya | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HEC regimens | 0 | 3 (2.3) | 2 (1.8) | 0 | 0 | 1 (0.8) | 3 (2.5) | 0 |
Cisplatin-based | – | 3 (2.3) | – | – | – | 1 (0.8) | – | – |
AC-based | – | – | 2 (1.8) | – | – | – | 3 (2.5) | – |